Dr. Reddy’s Laboratories has launched Clofarabine Injection, a therapeutic equivalent generic version of Clolar (clofarabine) Injection in the United States market, approved by the US Food & Drug Administration (USFDA). Clolar is a registered trademark of Genzyme Corporation.
Dr. Reddy’s Laboratories’ Clofarabine Injection is available in single-dose, 20 mL flint vials containing 20 mg of clofarabine in 20 mL of solution (1mg/mL). The Clolar brand and generic had US sales of around $53 million MAT for the most recent twelve months ended in September 2017, according to IMS Health.
Dr. Reddy’s Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.
